

**Supplemental Figure 1.** Post-NT sera from BC patients stimulate a CSC phenotype and contain elevated levels of MCPs. (**A**) Twenty pairs of pre- and post-NT sera from TNBC (*n*=8; black) or HER2<sup>+</sup> BC (*n*=12; blue) patients were analyzed for the activity to stimulate the ESA<sup>+</sup>CD44<sup>+</sup>CD24<sup>-/low</sup> population of BC cells. BT474 cells were cultured for 48 h in base medium supplemented with 10% human serum before flow cytometry analysis for the ESA<sup>+</sup>CD44<sup>+</sup>CD24<sup>-/low</sup> population. (**B**) Six pairs of pre- and post-NT sera from BC patients were examined by a human cytokine array. Boxed areas indicate CCL2, CCL8, and CCL7, from left to right, each in duplicate dots. (**C**) ESA<sup>+</sup>CD44<sup>+</sup>CD24<sup>-/low</sup> flow cytometry analyses using 6 pairs of sera (3 cases for each BC subtype) were performed as in **A** except that CCL2/7/8 neutralizing antibodies (NAb; 30 ng/ml; alone or all 3 combined) or control IgG were added during serum treatment. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001 (compared to the corresponding IgG group).